Recursion Pharmaceuticals logo

Recursion Pharmaceuticals

RXRX | NASDAQ
Chart Builder DCF Calculator
$2.90
-$0.29 (-8.95%)
At close: Nov 16, 2026, 4:00 PM ET
$2.91
+$0.01 (+0.33%)
After-hours: Nov 16, 2026, 7:57 PM ET
-8.95%

Rating

Updated: Nov 16, 2026
41.3
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #488/1021 (Top 48%)

Key Statistics

Market Data

Market Cap $1.81B
1D Range
2.87 3.13
52W Range
2.84 4.96

Valuation (TTM)

PE -3.22
PB 2.00
EV/EBITDA -3.29

Valuation (NTM)

Forward PE N/A
Forward PEG 0.08
Price Target $5.90
Loading financial charts...

Profile

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes,...

Sector Healthcare
Industry Biotechnology
Employees 600
IPO Date Apr 16, 2021
Fiscal Year January - December

Latest News

2 healthcare stocks to turn $10 into $100 by next year

5 days ago · finbold.com

2 healthcare stocks to turn $10 into $100 by next year
Recursion to Participate in Upcoming Investor Conferences

5 days ago · globenewswire.com

Recursion to Participate in Upcoming Investor Conferences
RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway

13 days ago · zacks.com

RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway
Recursion Pharmaceuticals, Inc. (RXRX) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2026 Earnings Call Transcript
What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

14 days ago · marketbeat.com

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates

14 days ago · zacks.com

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
Recursion Appoints Fred Hassan as Chair of the Board

14 days ago · globenewswire.com

Recursion Appoints Fred Hassan as Chair of the Board
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors

17 days ago · zacks.com

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

19 days ago · zacks.com

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

20 days ago · zacks.com

Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Earnings

Latest Earnings
Nov 2, 2026
EPS
-$0.22
Miss -0.45%
REV
$18.55M
Beat +25.30%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Hold
Price Target
$5.90
Upside
+103.45%
Buy (2)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.